First-in-human trial to investigate the tolerability, pharmacology, and pharmacokinetics of novel MDMA-like compounds versus a placebo in healthy subjects Acute effects of equivalent doses will be compared across the following compounds: MDMA, MDA, Lys-MDMA and Lys-MDA NEW YORK, Sept. 20, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”)…


Previous articleCOMPASS Pathways to participate in upcoming Jefferies Innovation in Mental Health Summit
Next articleHAVN Life Provides Corporate Update